Efficacy of Anticholinergics for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle-Aged Patients: A Single-Blinded, Prospective, Multi-Center Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients. Methods: Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients’ symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study. Results: There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine. Conclusions: Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.
Abstract
Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients. Methods: Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients’ symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study. Results: There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine. Conclusions: Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.
참고문헌 (14)
- Collins MM, "Prevalence and correlates of prostatitis in the health professionals follow-up study cohort", J Urol, 167, pp.1363~1366 (2002)
- Krieger JN, "NIH consensus definition and classification of prostatitis", JAMA, 282, pp.236~237 (1999)
- Luzzi GA, "Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management", J Eur Acad Dermatol Venereol, 16, pp.253~256 (2002)
- Liang CZ, "An epidemiological study of patients with chronic prostatitis", BJU Int, 94, pp.568~570 (2004)
- Schaeffer AJ, "Epidemiology and demographics of prostatitis", Eur urol suppl, 2, pp.5~10 (2003)
- Clemens JQ, "Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome", Urology, 56, pp.951~955 (2000)
- Fall M, "EAU guidelines on chronic pelvic pain", Eur Urol, 46, pp.681~689 (2004)
- Collins MM, "How common is prostatitis? A national survey of physician visits", J Urol, 159, pp.1224~1228 (1998)
- Dmochowski RR, "Overactive bladder in males", Ther Adv Urol, 1, pp.209~221 (2009)
- Schaeffer AJ, "Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study", J Urol, 168, pp.593~598 (2002)
- McNaughton Collins M, "Diagnosis and treatment of chronic abacterial prostatitis: a systematic review", Ann Intern Med, 133, pp.367~381 (2000)
- Litwin MS, "A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index", Urology, 60(6 Suppl), pp.14~18 (2002)
- Rosen R, "Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)", Eur Urol, 44, pp.637~649 (2003)
- 유영근, "Chronic Prostatitis", Chronic Pelvic Pain Syndrome을 가진 청장년 환자들에 대한 알푸조신의 치료효과, 2007, pp.48(8), 858~862[DOI]